| 0.9201 0.011 (1.24%) | 10-24 14:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.34  |
1-year : | 1.65 |
| Resists | First : | 1.15 |
Second : | 1.41 |
| Pivot price | 1.05 |
|||
| Supports | First : | 0.73 |
Second : | 0.61 |
| MAs | MA(5) : | 1.03  |
MA(20) : | 0.99 |
| MA(100) : | 0.81 |
MA(250) : | 11.27 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 37 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 74.16 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AEON ] has closed above bottom band by 27.2%. Bollinger Bands are 117.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.03 - 1.04 | 1.04 - 1.05 |
| Low: | 0.87 - 0.88 | 0.88 - 0.88 |
| Close: | 0.9 - 0.91 | 0.91 - 0.92 |
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Thu, 23 Oct 2025
Will AEON Biopharma Inc. outperform the market - Weekly Stock Recap & Low Risk Entry Point Guides - newser.com
Thu, 23 Oct 2025
Will AEON Biopharma Inc. Class stock return to pre crash levels - Weekly Profit Analysis & Smart Allocation Stock Reports - newser.com
Wed, 22 Oct 2025
How AEON Biopharma Inc. Class stock benefits from digital adoption - July 2025 WrapUp & Entry Point Strategy Guides - newser.com
Wed, 22 Oct 2025
Key resistance and support levels for AEON Biopharma Inc. - 2025 Big Picture & High Return Trade Opportunity Guides - newser.com
Tue, 21 Oct 2025
How AEON Biopharma Inc. Class stock valuation compares with sector - 2025 Dividend Review & Short-Term High Return Ideas - newser.com
Tue, 21 Oct 2025
What catalysts could drive AEON Biopharma Inc. stock higher - Weekly Risk Report & Entry Point Confirmation Signals - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 36.6 (%) |
| Held by Institutions | 23.8 (%) |
| Shares Short | 127 (K) |
| Shares Short P.Month | 623 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -597.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -6.24 |
| PEG Ratio | 0 |
| Price to Book value | -1.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|